Last week we talked about finding ways to make the T cells work harder and smarter – there are numerous ways to do this, but cytokines might be one interesting way to begin the search.
What about NK and other immune cells though, can we do the same with these too?
This week we are focusing on various cell therapy approaches with some academic and industry interviews to share, along with some analysis of arising issues as well as some new developments to review and discuss.
In the first of the series, we have an academic thought leader in the spotlight who had a few interesting points to make on novel cell therapies…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the AACR meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
In the fourth part of our mini-series in novel targets and agents in development we turn to novel cell therapy approaches that are perhaps under the radar for many observers.
While these might seem bleak times during a pandemic, there’s always a silver lining somewhere
While much attention has been focused on antigen loss or downregulation of the target wih adoptive cell therapies, research continues to evaluate various solutions to the problem.
One obvious way is to develop dual CARs or target multiple antigen targets of relevance to the tumour type being investigated.
There are other potential solutions being looked at, both in preclinical animal models and in translational work using cells from people treated with HSCT or CAR T cell therapies.
Here, we look at an alternative immunotherapy approach, which with time may have utility in both hematologic malignancies, as well as solid tumours…
To learn more from our oncology coverage and get a heads up on insights emerging our latest analysis and commentary subscribers can log-in or you can click to gain access to BSB Premium Content.
Heading Downtown for #CICON18
New York – It’s always good to see cancer researchers receive a Nobel prize.
I don’t think anyone at #CICON18 was surprised to see Dr Jim Allison as a recipient. I’m delighted to see Prof Honjo was also recognised too, as he discovered the PD-1 checkpoint target:
Moving on it’s time for some highlights of the first day of the meeting – a couple of interesting findings emerged from the proceedings…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.